Compare ROK & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ROK | NTRA |
|---|---|---|
| Founded | 1903 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.0B | 44.7B |
| IPO Year | 2004 | 2015 |
| Metric | ROK | NTRA |
|---|---|---|
| Price | $447.50 | $315.55 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 15 |
| Target Price | ★ $406.20 | $259.07 |
| AVG Volume (30 Days) | 833.0K | ★ 1.2M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.38% | N/A |
| EPS Growth | N/A | ★ 0.65 |
| EPS | ★ 9.44 | N/A |
| Revenue | ★ $6,666,000,000.00 | $210,939,000.00 |
| Revenue This Year | $7.46 | $18.08 |
| Revenue Next Year | $6.06 | $19.65 |
| P/E Ratio | $47.60 | ★ N/A |
| Revenue Growth | ★ 5.62 | N/A |
| 52 Week Low | $333.13 | $156.71 |
| 52 Week High | $497.36 | $326.03 |
| Indicator | ROK | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 45.43 | 67.71 |
| Support Level | $430.56 | $186.96 |
| Resistance Level | $465.80 | $326.03 |
| Average True Range (ATR) | 12.58 | 11.55 |
| MACD | -1.02 | 3.24 |
| Stochastic Oscillator | 25.32 | 87.46 |
With roots tracing back to the early 1900s, Rockwell Automation is the successor to Rockwell International, which spun off its avionics segment in 2001. It is a pure-play industrial automation company that operates through three segments. Its largest segment by revenue, intelligent devices, sells factory floor-level devices such as motors, drives, sensors, relays, and actuators. Its software and control segment sells visualization, simulation, and human-machine interface software and control products such as programmable controllers, computers, and operator terminals. Its smallest segment, lifecycle services, offers digital consulting, engineered-to-order services, and other outsourced services such as remote monitoring, cybersecurity, and asset and plant maintenance and optimization.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.